The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Connolly, Stuart J; Wallentin, Lars; Ezekowitz, Michael D; Eikelboom, John; Oldgren, Jonas; Reilly, Paul A; Brueckmann, Martina; Pogue, Janice; Alings, Marco; Amerena, John V; Avezum, Alvaro; Baumgartner, Iris; Budaj, Andrzej J; Chen, Jyh-Hong; Dans, Antonio L; Darius, Harald; Di Pasquale, Giuseppe; Ferreira, Jorge; Flaker, Greg C; Flather, Marcus D; ... (2013). The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 128(3), pp. 237-43. Baltimore, Md.: Lippincott Williams & Wilkins 10.1161/CIRCULATIONAHA.112.001139

Full text not available from this repository. (Request a copy)

During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Baumgartner, Iris

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0009-7322

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:41

Last Modified:

07 Jul 2014 12:49

Publisher DOI:

10.1161/CIRCULATIONAHA.112.001139

PubMed ID:

23770747

Web of Science ID:

000321897400018

URI:

https://boris.unibe.ch/id/eprint/17018 (FactScience: 224736)

Actions (login required)

Edit item Edit item
Provide Feedback